The Major Depressive Disorder drugs in development market research report provides comprehensive information on the therapeutics under development for Major Depressive Disorder, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Major Depressive Disorder. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Major Depressive Disorder and features dormant and discontinued products.
GlobalData tracks 127 drugs in development for Major Depressive Disorder by 103 companies/universities/institutes. The top development phase for Major Depressive Disorder is phase ii with 38 drugs in that stage. The Major Depressive Disorder pipeline has 120 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Major Depressive Disorder pipeline products market are: Shenox Pharmaceuticals, Psy Therapeutics and Alto Neuroscience.
The key targets in the Major Depressive Disorder pipeline products market include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A), Glutamate Ionotropic Receptor AMPA Type Subunit (AMPA Receptor or GRIA), and Glutamate Ionotropic Receptor NMDA Type Subunit (NMDAR or GRIN).
The key mechanisms of action in the Major Depressive Disorder pipeline product include 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Agonist with 17 drugs in Phase II. The Major Depressive Disorder pipeline products include 11 routes of administration with the top ROA being Oral and five key molecule types in the Major Depressive Disorder pipeline products market including Small Molecule, and Peptide.
Major Depressive Disorder overview
Major Depressive Disorder (MDD) is a common and severe mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in daily activities. Symptoms may include changes in appetite and sleep patterns, fatigue, difficulty concentrating, feelings of worthlessness, and thoughts of death or suicide. Diagnosis is based on the duration and intensity of these symptoms. Various factors, including genetics, brain chemistry, and life events, contribute to MDD. Treatment often involves a combination of psychotherapy, medication (antidepressants), and lifestyle changes. Timely intervention and ongoing support are crucial for managing and overcoming Major Depressive Disorder.
For a complete picture of Major Depressive Disorder’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
